多西他赛联合阿帕替尼二线治疗晚期非小细胞肺癌的临床评价

Docetaxel combined with apatinib in the second-line treatment of advanced non-small cell lung cancer

目的探讨晚期非小细胞肺癌患者二线治疗中多西他赛、阿帕替尼联合用药的效果及安全性。方法抽取唐山市人民医院2021年1月-2023年1月收治的晚期非小细胞肺癌患者80例为研究对象,以完全双盲法分为对照组和试验组,每组各40例,对照组行多西他赛治疗,试验组行多西他赛+阿帕替尼治疗,观察两组治疗后血清肿瘤因子变化情况,并评估两组治疗效果及安全性。结果①试验组治疗后血清肿瘤标志物CEA、VEGF、CYFRA21-1显著低于对照组;②试验组治疗总缓解率(55.00%)显著高于对照组(32.50%)(P<0.05);③试验组高血压发生率(55.00%)、手足综合征发生率(45.00%)、蛋白尿发生率(22.50%)显著高于对照组(17.50%、12.50%、0.00%)(P<0.05)。结论针对晚期非小细胞肺癌患者二线治疗中,在多西他赛基础上予以阿帕替尼治疗,可有效降低血清肿瘤标志物水平,提高抗肿瘤效果,加用阿帕替尼会增加高血压、手足综合征、蛋白尿等不良反应的发生率,但患者对不良反应均可耐受,该治疗方案值得推广。

Objective To investigate the efficacy and safety of docetaxel combined with Apatinib in second-line therapy for patients with advanced non-small cell lung cancer.Method Eighty patients with advanced non-small cell lung cancer admitted to our hospital from January 2021 to January 2023 were selected as research objects,and were divided into control group and experimental group with 40 cases each by completely double-blind method.The control group received docetaxel treatment and the experimental group received docetaxel+Apatinib treatment.The changes of serum tumor factors in the two groups after treatment were observed,and the therapeutic effect and safety of the two groups were evaluated.Results①Serum tumor markers CEA,VEGF and CYFRA21-1 in experimental group were significantly lower than those in control group after treatment;②The total remission rate of experimental group was 55.00%significantly higher than that of control group(32.50%)(P<0.05);③The incidence of hypertension(55.00%),hand-foot syndrome(45.00%)and albuminuria(22.50%)in experimental group were significantly higher than those in control group(17.50%,12.50%,0.00%)(P<0.05).Conclusions In second-line therapy for patients with advanced non-small cell lung cancer,Apatinib therapy on the basis of docetaxel can effectively reduce the level of serum tumor markers and improve the antitumor effect.The addition of Apatinib can increase the incidence of adverse reactions such as hypertension,hand and foot syndrome and albuminuria,but patients can tolerate the adverse reactions,and this treatment regimen is worth promoting.